RapTr2022 is developed by Aragen’s expert scientific team at the California campus with more than two decades of experience in planning and designing engineered cell lines for therapeutic, diagnostic, and reagent generation applications. Our newly established platform has proven capabilities to produce a range of biologics, including human, mouse, canine and feline IgGs, fusion proteins, enzymes, hormones, cytokines, mini bodies and bispecific antibodies.
A key feature of RapTr2022 is the single-cell printer from CYTENA and Solentim imager for rapid clonality assurance to shorten cycle times for FDA submissions. Assurance of production cell bank clonality ensures consistency of product quality and process performance throughout the lifecycle of the product. Documentation of clonality is essential as part of IND process and is mandatory by the time of BLA (Biological Licence Application).
RapTr2022 is supported by very strong analytical capabilities that provide clients with a variety of methodologies for testing the purity, identity, potency, and stability of their monoclonal antibody (mAb) and recombinant protein products. These procedures are critical for the analysis and characterization of biologics as well as guaranteeing the product’s safety, stability, and efficacy at all stages of development.
With the launch of the RapTr2022 platform, our goal is to deliver clients’ products to clinics at speed while minimising risk and maximising efficiency.
